Systemic immunologic effects of long-term dupilumab treatment in severe eosinophilic asthma beyond clinical outcomes
IntroductionDupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling, is used in severe eosinophilic asthma to improve clinical control and suppress type 2 inflammation.MethodsWe evaluated the clinical and systemic immunologic effects of dupilumab, focusing on type 2 biomarkers, total and a...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2026-06-01
|
| Saila: | Frontiers in Allergy |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.frontiersin.org/articles/10.3389/falgy.2026.1873964/full |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|